Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Visby Medical (LH) expanded consumer access to its FDA-authorized at-home Women’s Sexual Health Test, a palm-sized PCR device delivering lab-quality results in ~30 minutes for chlamydia, gonorrhea, and trichomoniasis. As of November 2025 the test is purchasable on questhealth.com, and it is now available on Labcorp OnDemand; Ovia Health by Labcorp plans employer/health-plan distribution in early 2026. The test enables a self-collected vaginal swab, secure app results, and links to same-day virtual care and medication via third-party providers, aiming to reduce testing delays and untreated STI complications.
NAMSA (ARCHIMED portfolio) completed the acquisition of the U.S. assets of Labcorp's Early Development medical device testing business on Jan 8, 2026, expanding NAMSA's U.S. service portfolio to include biocompatibility, microbiological, analytical testing and preclinical research.
The deal positions NAMSA as a broader end-to-end MedTech testing partner, transfers Labcorp Early Development device projects to NAMSA facilities in Ohio, Minnesota, Georgia and California, and is NAMSA's 10th acquisition since joining ARCHIMED in 2020.
Labcorp (NYSE: LH) will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, 2026 at 4:30 p.m. PT. A live audio webcast will be available on the company investor relations site ir.Labcorp.com and will be archived for replay.
The presentation offers investors and analysts direct access to management commentary on strategy and market outlook; no financial results or guidance are included in this announcement.
Labcorp (NYSE: LH) completed the acquisition of select ambulatory outreach laboratory assets from Community Health Systems subsidiary CHS for approximately $194 million in cash on December 2, 2025.
The sale covers outreach lab services, certain patient service centers and in‑office phlebotomy locations in 13 states. CHS will continue to operate inpatient and emergency department laboratories and hospital-based lab services. Labcorp said the transaction expands access to its specialty testing menu, data analytics and digital tools for CHS‑affiliated patients and providers.
Labcorp (NYSE: LH) announced the appointment of Victor Bulto to its Board of Directors, effective December 1, 2025. Bulto currently leads Novartis' U.S. business, a $20+ billion operation, and brings 25 years of global healthcare leadership across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.
Labcorp highlighted his experience in transformation, technology and automation, and commercial strategy as supportive of its long-term growth priorities in precision medicine, patient access to novel therapies, and innovation through science and technology.
Labcorp (NYSE: LH) announced that Labcorp Plasma Detect, a tumor‑informed blood assay for detecting molecular residual disease (MRD) from circulating tumor DNA, was featured in two peer‑reviewed studies published Nov 19, 2025.
A Nature Medicine study in diffuse pleural mesothelioma reported that both neoadjuvant immune regimens were safe, enabled most patients to undergo surgery, and that Plasma Detect tracked early disease progression and predicted long‑term progression‑free survival. A Clinical Cancer Research study found that lymph drain fluid collected 24 hours after head and neck cancer surgery contained more tumor DNA than simultaneous plasma and that lymph‑based testing identified residual cancer missed by pathology.
Labcorp (NYSE: LH) reported third-quarter 2025 results with revenue $3.56B (up 8.6% YoY) and diluted EPS $3.12 versus $2.00 a year ago. Adjusted EPS was $4.18 (up 19.4% YoY). Operating income margin improved to 11.1% and free cash flow for the quarter was $280.5M.
The company updated 2025 guidance: enterprise revenue growth of 7.4%–8.0% (midpoint lowered ~40 bps), adjusted EPS $16.15–$16.50 (midpoint +$0.05) and free cash flow $1.17B–$1.29B (midpoint +$25M). Labcorp announced multiple asset acquisitions, a $0.72 quarterly dividend and $25M of share repurchases in the quarter.
Labcorp (NYSE: LH) will offer Roche's FDA-cleared Elecsys pTau181 blood test nationwide by early 2026 to aid initial assessment of Alzheimer's-related amyloid pathology in primary care. The test is intended for adults 55+ with cognitive complaints and measures plasma phosphorylated Tau 181. Roche reported a 97.9% negative predictive value (NPV), meaning a negative result aligns with a negative amyloid PET and lowers the likelihood that cognitive impairment is due to amyloid pathology. Testing can be performed at a clinician's office or at any of Labcorp's >2,200 patient service centers.
Praia Health, Providence, and Labcorp (LH) announced a collaboration that connected Praia Health’s patient experience platform with Labcorp’s scheduling and lab-ordering systems to streamline lab booking and patient workflows.
Key outcomes include an 8-fold increase in scheduled appointments, a 52% increase in lab bookings via digital notifications, 52% higher patient bill-pay engagement, 37% of canceled appointments rebooked within 30 days, and 23% of appointments self-modified or canceled via the app—reducing no-shows. The partners report improved patient engagement, operational efficiency, and plans to explore genomics, chronic care, at-home collection, and clinical trial recruitment.
Labcorp (NYSE: LH) announced that its Board declared a quarterly cash dividend of $0.72 per share. The dividend is payable on December 11, 2025 to shareholders of record at the close of business on November 26, 2025.